TABLE 1

Provisional Radiation to Target Lesions and Bone Marrow

Target lesionsBone marrow
Patient no.DiseaseStageRadioimmunotherapy activity (GBq)SitemGy/MBqIntended dose (Gy)mGy/MBqIntended dose (Gy)
1SLL-NHLIIIBNot eligibleLeft axillary LN0.84.440.121.1
2SLL-NHLIIIBS5.55Left laterocervical LN3.318.3150.180.1
3HLIIIBS5.55Lung, right middle lobe2.5140.231.3
4HLIVB3.7Right lung, nodular lesion0.93.330.190.69
Chest wall,anterior mass3.211.84
5HLIVB3.7 (n = 5)Left lung, basal nodular lesion5.620.720.230.85
Right axillary LN13.7
6HLIVBNot eligibleLumboaortic LN0.420.130.48
7FL-NHLIIIANot eligibleLeft axillary LN0.21.110.211.2
Right axillary LN0.10.555
Right cervical LN0.42.22
Right inguinal LN0.52.77
8HLIVBNot eligibleAny0.271.42
9MMIII3.70.240.9
10MMIII1.850.210.38
11MMIIINot applied, withdrew from study0.431.58
12HLIVB3.7 (n = 2)Right paracardiac LN20.776.590.190.72
13HLIVB3.7Right dorsal muscle0.62.440.632.55
Right axillary LN2.510.17
14HLIVB3.7 (n = 2)Costopleural lesion15.462.70.190.76
15HLIVB3.7 (n = 2)Aortopulmonary window LN5.825.750.361.6
16HLIVBNot applied, rapid progressMediastinal anterior mass8.932.933.211.8
17DLBCLIIIA3.7Left inguinal LN3.512.950.240.9
18HLIVB1.85Right iliac LN35.550.220.34
  • SLL = small lymphocytic lymphoma; LN = lymph nodes.